$1.44
0.70%
NYSE, May 02, 10:00 pm CET
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Adc Therapeutics SA Stock price

$1.44
+0.11 8.27% 1M
-1.58 52.32% 6M
-0.55 27.64% YTD
-3.29 69.56% 1Y
-10.48 87.92% 3Y
-28.21 95.14% 5Y
-28.21 95.14% 10Y
NYSE, Closing price Fri, May 02 2025
+0.01 0.70%
ISIN
CH0499880968
Symbol
ADCT
Sector
Industry

Key metrics

Market capitalization $142.82m
Enterprise Value $14.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.21
P/S ratio (TTM) P/S ratio 2.02
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1.84%
Revenue (TTM) Revenue $70.84m
EBIT (operating result TTM) EBIT $-130.65m
Free Cash Flow (TTM) Free Cash Flow $-125.17m
Cash position $250.87m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 1.95
EV/Sales forward 0.20
Short interest 5.81%
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Adc Therapeutics SA forecast:

Buy
100%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
71 71
2% 2%
100%
- Direct Costs 9.23 9.23
65% 65%
13%
62 62
7% 7%
87%
- Selling and Administrative Expenses 79 79
22% 22%
112%
- Research and Development Expense 110 110
15% 15%
155%
-127 -127
22% 22%
-180%
- Depreciation and Amortization 3.28 3.28
-
5%
EBIT (Operating Income) EBIT -131 -131
22% 22%
-184%
Net Profit -158 -158
34% 34%
-223%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
PRNewsWire
7 days ago
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs LAUSANNE, Switzerland , April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in ...
Neutral
PRNewsWire
about one month ago
LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant"). The Grants were offered as mate...
Neutral
PRNewsWire
about one month ago
LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ...
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 265
Founded 2011
Website www.adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today